Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Date:12/9/2008

ith a statistically significant improvement in agitation at 10 minutes post-dose, which was sustained through the 24-hour study period. In all of the reported clinical trials to date, AZ-004 has been shown to be safe and generally well tolerated in patients and subjects.

About Symphony Allegro

In December 2006, Alexza entered into a collaboration with Symphony Capital LLC, a biotech-focused private equity firm. Under the terms of the agreement, Alexza and Symphony Capital established Symphony Allegro, Inc., which is providing funding to Alexza to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a license to certain intellectual property rights for the selected product candidates. Through a purchase option, Alexza retains the exclusive right, but not the obligation, to acquire 100% of the equity of Symphony Allegro at specified prices during the term of the agreement. If Alexza chooses not to exercise the purchase option, Symphony Allegro retains the rights to the product candidates. The purchase option expires December 1, 2010.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has five product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
2. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... officer Howie Rosen will be presenting at ... Tim Morris will be presenting at JMP Securities ... as follows: Jefferies 2015 Healthcare Conference Date: ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 ... has announced the addition of the "North ... & Graft), by Application (Surgical Wound, & Ulcer), ... Forecast to 2019" report to their offering. ... wound care market is estimated to grow at ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: ... employee Greg Watson , the company,s vice president of ... the company,s common stock, at a per share exercise price ... The stock option was granted pursuant to Cardica, Inc.,s Inducement ... in May 2015 under Rule 5653(c)(4) of the Nasdaq Global ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2
... 1, 2011 Every year thousands of children are hospitalized ... for them. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Teens share ... by colorful pills that look like candy. ... how you can prevent harm by locking your medicine up. ...
... N.J., Nov. 1, 2011 Quest Diagnostics Incorporated (NYSE: ... diagnostic testing, information and services, today announced the CE ... & RSV Direct test on the 3M™ Integrated Cycler. ... uses a proprietary technique to eliminate nucleic-acid sample extraction, ...
Cached Medicine Technology:Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 2Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 3
(Date:5/22/2015)... CA (PRWEB) May 22, 2015 ... Sunset Plaza Dental announces that they are now ... restorative and other dental treatments. At consultations, patients ... them. Questions regarding what certain treatments can achieve ... be covered during this initial appointment. If treatments ...
(Date:5/22/2015)... 22, 2015 A Phase 3 ... American Society of Clinical Oncology (ASCO)’s annual meeting ... rates for those patients who received bevacizumab in ... pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is an antibody ... is already routinely used to treat many other ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 In an ... Parker and Sons is offering to donate $5 dollars ... an AC unit or water softening system. Customers have ... Parker and Sons gets business; and the Special Olympics ... The Special Olympics helps over 4.4 million athletes, and ...
(Date:5/22/2015)... A new program for the "In America" television ... Physical Therapy. , James Earl Jones will host ... physical therapy and discusses how the exercises can decrease ... of ailments and injuries. Physical therapists work with ... enhances daily activities such as house cleaning and shopping, ...
(Date:5/22/2015)... 22, 2015 Yisrayl Hawkins, Pastor and Overseer ... a new letter calling on religious leaders to make changes ... was published on his blog, discusses the history of war, ... to stop it. Yisrayl says mankind was created to lead ... in today’s society. , “Yahweh created mankind, according to ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2
... more attention to choosing the doctor, not the device ... as a safe and long-lasting way to alleviate hip-related ... fails, the problem more often lies with surgical error ... , , Dislocation of the implant was the most common ...
... gene is a key to understanding, and perhaps killing, ... only to reawaken years later, researchers at The University ... the December Journal of Clinical Investigation . , ... ARHI acts as a switch for autophagy, or self-cannibalization, ...
... that Lewy bodies, clumps of aggregated proteins inside ... Parkinson,s disease and other neurodegenerative diseases. , The ... protein recycling and waste disposal, leading to the ... cells? , One possible answer: by breaking a ...
... supplementation was found to be effective in relieving pain ... chronic pancreatitis (CP), reports a new study in ... the pancreas in which patients experience abdominal pain (in ... Pain is the major problem in 90 percent of ...
... from presence of salicylic acid in study participants , , ... key component that gives aspirin its anti-inflammatory and pain-relieving ... own, a new study suggests. , Salicylic acid (SA) ... who had not taken aspirin recently -- especially vegetarians. ...
... organ improved odds, study shows , , WEDNESDAY, Dec. 31 ... donated kidney raised the chances of a successful transplant ... European researchers report. , The study, published in the ... of Medicine , got generally favorable reviews from American ...
Cached Medicine News:Health News:Surgeons Often Are Blamed When Hip Replacements Fail 2Health News:Surgeons Often Are Blamed When Hip Replacements Fail 3Health News:Dormant cancer cells rely on cellular self-cannibalization to survive 2Health News:Toxicity mechanism identified for Parkinson's disease 2Health News:Antioxidants offer pain relief in patients with chronic pancreatitis 2Health News:A Better Method of Kidney Storage 2Health News:A Better Method of Kidney Storage 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: